SCHEMBL3249137

SCHEMBL3249137

CNC(=O)NCCN(c1ccc(Cl)cc1Cc1c(F)cccc1F)S(=O)(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.49
HCRTR2 O43614 2/20 0.44
HCRTR1 O43613 1/20 0.44
MAPT P10636 4/20 0.41
TP53 P04637 1/20 0.41
MCOLN3 Q8TDD5 3/20 0.41
POLB P06746 2/20 0.41
PTGER1 P34995 5/20 0.41
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 1/20 0.39
OXTR P30559 1/20 0.39
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3250401 0.93 PKM (0.49) PKMHCRTR2HCRTR1MAPTTP53
SCHEMBL3247054 0.93 PKM (0.49) PKMHCRTR2HCRTR1MAPTTP53
SCHEMBL3244439 0.92 POLB (0.48) PKMHCRTR2HCRTR1MAPTTP53
SCHEMBL3248997 0.91 PKM (0.45) PKMHCRTR2HCRTR1MAPTTP53
SCHEMBL3256037 0.91 PKM (0.48) PKMHCRTR2HCRTR1MAPTTP53
SCHEMBL3256157 0.90 PKM (0.44) PKMHCRTR2HCRTR1MAPTTP53
SCHEMBL4870970 0.90 PKM (0.48) PKMHCRTR2HCRTR1MAPTTP53
SCHEMBL4871023 0.89 PKM (0.52) PKMHCRTR2HCRTR1MAPTTP53
SCHEMBL14441666 0.89 PTGER1 (0.41) PKMMAPTPTGER1TSHR
SCHEMBL14107575 0.88 PKM (0.45) PKMHCRTR2HCRTR1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 PKM 2524/4885HCRTR2 1/4885HCRTR1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.